Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol
Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions
using a single-dose, randomized, 3-treatment, 3-period, crossover design.